



1181 **Supplemental Materials:**
1182 Supplemental Figures 1-7
1183 Supplemental Table 1
1184 Supplemental Movies 1-10
1185
1186




1187
1188
1189 **Supplemental figure 1. Co-trafficking of HCV particles with host proteins. (A)**
1190 Representative montages from live cell fluorescence microscopy of TC-core HCV particles co-
1191 trafficking with GFP-LC3. **(B)** Velocity of individual TC-core puncta co-trafficking with AP1 or
1192 AP2. Experiments were replicated twice.

1193
1194
1195
1196
1197
1198
1199
1200
1201




1202
1203
1204 **Supplemental figure 2. 7745 Kd.** Kd of compound 7745 for AAK1 as measured by a
1205 KINOMEscan kinase assay (DiscoverX).

1206




1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220

Supplemental figure 3. Dose response of DENV infection to sunitinib and erlotinib. (A) Dose response of overall DENV infection to sunitinib and erlotinib measured by plaque assays at 72 hours post-infection. Assay detection limit is marked with a dotted line. **(B)** Dose response of overall DENV infection to sunitinib/erlotinib combinations measured by luciferase assays at 48 hours post-infection and normalized to DMSO control. All data shown are representative of at least two experiments with 6 biological replicates each. Shown are mean +/- s.d. PFU, plaque forming units.




1221
1222
1223
1224
1225
1226
1227
1228
1229
1230

Supplemental figure 4. Activity of sunitinib and erlotinib against additional flaviviruses. (A) Overall infection of murine embryonic fibroblast cells with WNV (black) and relative cell viability (blue) following 24 hour treatment with sunitinib measured by focus formation and MTT assays, respectively. **(B)** Overall infection of Huh7 cells with ZIKV (black) and relative cell viability (blue) following 48 hour treatment with sunitinib and erlotinib measured by plaque and alamarBlue assays, respectively. Shown are representative experiments from at least two conducted with 2 (panel A) and 6 (panel B) biological replicates each.




1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241

Supplemental figure 5. Regulation of EBOV entry and overall infection by AAK1, GAK and their pharmacological inhibitors. (A, B) Quantification of rVSV-GP EBOV entry measured in Vero cells at 3 hours post-infection by real-time PCR following knockdown of AAK1 and GAK (A) or inhibitor treatment (B). Plotted is expression of EBOV GP normalized to GAPDH. Shown are mean +/- s.d. (n=3) relative to NT (A) or DMSO (B) controls (two-tailed unpaired t-test). **p<0.01, ***p<0.001 by 1-way ANOVA followed by Dunnett's multiple comparisons test. Shown are representative experiments from at least two conducted.



1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253

Supplemental figure 6. AAK1 and GAK inhibitors are protective in a dengue murine model. (A) Effect of sunitinib (SM) and erlotinib (E) on viral load in serum, spleen and liver on day 3 post-infection of AG-B6 mice measured by plaque assays. Drugs were administered intraperitoneally once daily. Doses are in mg/kg. *p<0.05, ***p<0.001 (nonparametric Mann-Whitney test). Experiments were replicated twice. (B) Quantification of drug serum levels in AG-B6 mice by liquid chromatography-tandem mass spectrometry following intraperitoneal administration of a single dose of 30 mg/kg sunitinib and 30 mg/kg erlotinib (n=2). Analysis was performed by Integrated Analytical Solutions (Berkeley, Ca). Shown are representative experiments from at least two conducted.



1254
1255

1256

Supplemental figure 7. siRNA screen testing the involvement of kinases inhibited by sunitinib and erlotinib in DENV infection. Overall DENV infection (black) measured by luciferase assays and relative cell viability (blue) measured by alamarBlue assays at 48 hours post-infection of siRNA-transfected Huh7 cells. Data are expressed relative to NT siRNA. Data are an average of two independent screens with 8 replicates each.

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285
1286
1287

Supplemental Table 1. siRNA library against top 27 kinase targets of sunitinib and erlotinib.

Pool Catalog #	Duplex Catalog #	Gene Symbol	GENE ID	Gene Accession	Sequence
L-003150-00	J-003150-09	KIT	3815	NM_000222	UAAAGGAAACGCUCGACUA
L-003150-00	J-003150-10	KIT	3815	NM_000222	AAACACGGCUUAAGCAAUU
L-003150-00	J-003150-11	KIT	3815	NM_000222	AACAGAACCUUCACUGAUA
L-003150-00	J-003150-12	KIT	3815	NM_000222	GUUCAAGCAGGAAGAUA
L-003137-00	J-003137-09	FLT3	2322	NM_004119	CAAGAAACGACACCGGAUA
L-003137-00	J-003137-10	FLT3	2322	NM_004119	GAAUUUAAGUCGUGUGUUC
L-003137-00	J-003137-11	FLT3	2322	NM_004119	GCA AUGAUUUUUGGGACUA
L-003137-00	J-003137-12	FLT3	2322	NM_004119	CGCAACAGCUUAUGGAAUU
L-003966-00	J-003966-12	MAP2K5	5607	NM_145162	CCUCCAUAUGCUAGUAAA
L-003966-00	J-003966-13	MAP2K5	5607	NM_145162	UAAGUGCGAUUCAUAUU
L-003966-00	J-003966-14	MAP2K5	5607	NM_145162	GGAGCCAUUUUGUACAUUUC
L-003966-00	J-003966-15	MAP2K5	5607	NM_145162	GAAUUGCAGUAGCAGUUGU
L-003148-00	J-003148-09	KDR	3791	NM_002253	GGGCAUGUACUGACGAUUA
L-003148-00	J-003148-10	KDR	3791	NM_002253	CUACAUUGUUCUUCGGAUA
L-003148-00	J-003148-11	KDR	3791	NM_002253	GGAAUCUCUUGCAAGCUA
L-003148-00	J-003148-12	KDR	3791	NM_002253	GCGAUGCCUCUUCUGUAA
L-003162-00	J-003162-11	PDGFRA	5156	NM_006206	CGAGACUCCUGUAACCUUA
L-003162-00	J-003162-12	PDGFRA	5156	NM_006206	GAGCUUCACCUAUCAGUU
L-003162-00	J-003162-13	PDGFRA	5156	NM_006206	GACAGUGCCAUUAUACUA
L-003162-00	J-003162-14	PDGFRA	5156	NM_006206	GAAUAGGGAUAGCUUCCUG
L-003163-00	J-003163-10	PDGFRB	5159	NM_002609	CAACGAGUCUCCAGUGCUA
L-003163-00	J-003163-11	PDGFRB	5159	NM_002609	GAGCGACGGUGGCUACAUG
L-003163-00	J-003163-12	PDGFRB	5159	NM_002609	GAAGCCACGUUACGAGAUC
L-003163-00	J-003163-13	PDGFRB	5159	NM_002609	GGUGGGCACACUACA AUUU
L-003114-00	J-003114-10	EGFR	1956	NM_201283	CAAAGUGUGUAACGGAAUA
L-003114-00	J-003114-11	EGFR	1956	NM_201283	CCAUAUAUGCUACGAAUUA
L-003114-00	J-003114-12	EGFR	1956	NM_201283	GUAACAAGCUCACGCAGUU
L-003114-00	J-003114-13	EGFR	1956	NM_201283	CAGAGGAUGUCAAUAACU
L-003136-00	J-003136-10	FLT1	2321	NM_002019	GCCGGAAGUUGUAUGGUUA
L-003136-00	J-003136-11	FLT1	2321	NM_002019	UAGAAAGGGCUUCAUCAUA
L-003136-00	J-003136-12	FLT1	2321	NM_002019	GUGGUCAGCUCUAGAAUUU
L-003136-00	J-003136-13	FLT1	2321	NM_002019	GUCAUCCUCCGCCGGGUUA
L-003109-00	J-003109-10	CSF1R	1436	NM_005211	GGAAGAUCAUCGAGAGCUA
L-003109-00	J-003109-11	CSF1R	1436	NM_005211	GGUGAAGGAUGGAUACCAA
L-003109-00	J-003109-12	CSF1R	1436	NM_005211	GUAACGUGCUGUUGACCAA
L-003109-00	J-003109-13	CSF1R	1436	NM_005211	CCAGCAGCGUUGAUGUUAA
L-005023-00	J-005023-06	PHKG1	5260	NM_006213	GCACAGGACUUCUAUGAGA
L-005023-00	J-005023-07	PHKG1	5260	NM_006213	GCACUGCGUCAUCAUGUA
L-005023-00	J-005023-08	PHKG1	5260	NM_006213	CCAGAAAGAUCAUGCGAGC
L-005023-00	J-005023-09	PHKG1	5260	NM_006213	GAAGGACACUUAUGAGACC
L-004881-00	J-004881-13	PHKG2	5261	NM_000294	GAUCCGACUUCAGAUUUC
L-004881-00	J-004881-14	PHKG2	5261	NM_000294	CUACGAGUCUUCUAGCUUC
L-004881-00	J-004881-15	PHKG2	5261	NM_000294	GGGAGACUCUGCUGCUAUA
L-004881-00	J-004881-16	PHKG2	5261	NM_000294	CGAGAAGCUUCGAGAGUUG
L-003104-00	J-003104-10	AXL	558	NM_001699	ACAGCGAGAUUUUAUGACUA
L-003104-00	J-003104-11	AXL	558	NM_001699	GGUACCGGCUGGCGUAUCA
L-003104-00	J-003104-12	AXL	558	NM_001699	GACGAAUCCUCUAUGUCA
L-003104-00	J-003104-13	AXL	558	NM_001699	GAAGGAGACCCGUUAUGGA
L-003256-00	J-003256-17	CHEK2	11200	NM_145862	GUAAGAAGUAGCCAUAAA
L-003256-00	J-003256-18	CHEK2	11200	NM_145862	GCAUAGGACUCAAGUGUCA
L-003256-00	J-003256-19	CHEK2	11200	NM_145862	GUUGUGAACUCCGUGGUUU
L-003256-00	J-003256-20	CHEK2	11200	NM_145862	CUCAGGAACUCUAUUCUUAU
L-005377-00	J-005377-05	STK17A	9263	NM_004760	UUUAGAAGGUGUUCACUUU

L-005377-00	J-005377-06	STK17A	9263	NM_004760	UAACAUUUGUCAUGCUUAC
L-005377-00	J-005377-07	STK17A	9263	NM_004760	GAAUAUCACCUUUCUUAGG
L-005377-00	J-005377-08	STK17A	9263	NM_004760	CAUAUACUCUJAGGACAAUG
L-004168-00	J-004168-09	STK10	6793	NM_005990	GAGCAAUUGCAUAAACGUU
L-004168-00	J-004168-10	STK10	6793	NM_005990	GAUCAUGAUUGAGUUCUGU
L-004168-00	J-004168-11	STK10	6793	NM_005990	CAAGCGGACACGCAAUUU
L-004168-00	J-004168-12	STK10	6793	NM_005990	GGAGAACCAUACUCAGAAC
L-003478-01	J-003478-17	CSNK1D	1453	NM_001893	ACGAAAGGAUUAGCGAGAA
L-003478-01	J-003478-18	CSNK1D	1453	NM_001893	CGACCUCACAGGCCGACAA
L-003478-01	J-003478-19	CSNK1D	1453	NM_001893	GCCAAGAAGUACCGGGAUG
L-003478-01	J-003478-20	CSNK1D	1453	NM_001893	AGGCUACCCUCCGAAUUU
L-003479-00	J-003479-10	CSNK1E	1454	NM_001894	CCACCAAGCGCCAGAAGUA
L-003479-00	J-003479-11	CSNK1E	1454	NM_001894	CCUCCGAAUUCUCAACAU
L-003479-00	J-003479-12	CSNK1E	1454	NM_001894	CGACUACUCUUACCUACGU
L-003479-00	J-003479-13	CSNK1E	1454	NM_001894	GAUCAGCCGCAUCGAGUAU
L-003586-00	J-003586-07	MAP4K1	11184	NM_007181	GAUACAUGAGCUGUGUGA
L-003586-00	J-003586-08	MAP4K1	11184	NM_007181	CAACAACGUUCUCAUGUCU
L-003586-00	J-003586-09	MAP4K1	11184	NM_007181	GGAGUUAUCUCUGGUUGCA
L-003586-00	J-003586-10	MAP4K1	11184	NM_007181	GAAAGGACCCUCCAUIGGG
L-004760-00	J-004760-12	IRAK1	3654	NM_001025243	GAUGAGGGCUGACACCCA
L-004760-00	J-004760-13	IRAK1	3654	NM_001025243	CGAAGAAAGUGAUGAAUUU
L-004760-00	J-004760-14	IRAK1	3654	NM_001025243	GCAAUUCAGUUUCUACAUC
L-004760-00	J-004760-15	IRAK1	3654	NM_001025243	GAGCUGAUGUGUUCACCG
L-003144-00	J-003144-13	ITK	3702	NM_005546	AGACAUCAGUACCGGAUUU
L-003144-00	J-003144-14	ITK	3702	NM_005546	ACAGUUUGGUGCCUAAAUA
L-003144-00	J-003144-15	ITK	3702	NM_005546	UCAACUAUCACCAACAUAA
L-003144-00	J-003144-16	ITK	3702	NM_005546	CCACACACGUCUACCAGAU
L-004157-00	J-004157-06	STK4	6789	NM_006282	CCAGAGCUAUGGUCAGAU
L-004157-00	J-004157-07	STK4	6789	NM_006282	GCCCUCAUGUAGUCAAAUA
L-004157-00	J-004157-08	STK4	6789	NM_006282	GAUGGGCACUGUCCGAGUA
L-004157-00	J-004157-09	STK4	6789	NM_006282	UAAAGAGACCGGCCAGAUU
L-027171-01	J-027171-13	MYLK4	340156	NM_001012418	GAGAAGAGUUGGCCAAUAA
L-027171-01	J-027171-14	MYLK4	340156	NM_001012418	CGGAAAGGAUGCCCGUCA
L-027171-01	J-027171-15	MYLK4	340156	NM_001012418	GAAAUUAAGCACCGAUGUA
L-027171-01	J-027171-16	MYLK4	340156	NM_001012418	GUGAAGGCCACAUGCGAAU
L-003614-00	J-003614-05	PAK3	5063	NM_002578	CAAAGUAAACGAAGCACUA
L-003614-00	J-003614-06	PAK3	5063	NM_002578	GGGCAUCAGGUACUGUUUA
L-003614-00	J-003614-07	PAK3	5063	NM_002578	GAGAGACUGUCAGCUGUAU
L-003614-00	J-003614-08	PAK3	5063	NM_002578	GCAUUGGGCACGAUUACUC
L-003170-00	J-003170-09	RET	5979	NM_020630	CAGGAGGGCUCGCCGAUUU
L-003170-00	J-003170-10	RET	5979	NM_020630	AGAGACGGCUGGAGUGUGA
L-003170-00	J-003170-11	RET	5979	NM_020630	GGGCGACCGUACAUGACUA
L-003170-00	J-003170-12	RET	5979	NM_020630	GUCCCGAGAUGUUUAUGAA
L-004663-00	J-004663-06	RPS6KA2	6196	NM_001006932	CAAGCGAUGUGUGCAUAAA
L-004663-00	J-004663-07	RPS6KA2	6196	NM_001006932	UAAUGGAGCUGAUGCGUGG
L-004663-00	J-004663-08	RPS6KA2	6196	NM_001006932	GGAACACGCUGUACCGGAA
L-004663-00	J-004663-09	RPS6KA2	6196	NM_001006932	GCAAUUGGGCCAGACGAUA
L-005383-00	J-005383-07	STK33	65975	NM_030906	GAGCAUAGGCGUCGUAAUG
L-005383-00	J-005383-08	STK33	65975	NM_030906	GCUGAUAGUGGCUUAGAUA
L-005383-00	J-005383-09	STK33	65975	NM_030906	CGAUCAGCUAUAGCAUUA
L-005383-00	J-005383-10	STK33	65975	NM_030906	GAAGCAAAGUAGGAGUGAA
L-005396-00	J-005396-06	ULK2	9706	NM_014683	GUGGAGACCUCGCAGAUUA
L-005396-00	J-005396-07	ULK2	9706	NM_014683	UCAGACCACUCAUGUGAUA
L-005396-00	J-005396-08	ULK2	9706	NM_014683	CGAUUAAAUUCUGCAUCA
L-005396-00	J-005396-09	ULK2	9706	NM_014683	UCCAAGAUCUGCAGUGGUA
L-005300-02	J-005300-05	AAK1	22848	NM_014911	CCUCGGACCUCUCAACAAA
L-005300-02	J-005300-07	AAK1	22848	NM_014911	ACAAAAGGCCGGAUUAUUU
L-005300-02	J-005300-08	AAK1	22848	NM_014911	GGAAGGUGGAUUUGCUAUU
L-005300-02	J-005300-17	AAK1	22848	NM_014911	GCGUAUUCUCAGUGACGUA

D-001810-10	D-001810-01	NT Control	N/A	N/A	UGGUUUACAUGUCGACUAA
D-001810-10	D-001810-02	NT Control	N/A	N/A	UGGUUUACAUGUUGUGUGA
D-001810-10	D-001810-03	NT Control	N/A	N/A	UGGUUUACAUGUUUUCUGA
D-001810-10	D-001810-04	NT Control	N/A	N/A	UGGUUUACAUGUUUCCUA

1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328

Supplemental Videos

Supplemental Video 1. Co-trafficking of TC-core HCV with AP1. Representative video. TC-core (green), AP1 (red).

Supplemental Video 2. Co-trafficking of TC-core HCV with AP2. Representative video. TC-core (green), AP2 (red).

Supplemental Video 3. Co-trafficking of TC-core HCV with LC3. Representative video. TC-core (red), LC (green).

Supplemental Video 4. Co-trafficking of TC-core Y136A HCV with AP2. Representative video. Mutant TC-core (green), AP2 (red).

Supplemental Video 5. Co-trafficking of TC-core HCV with AP1 upon vehicle treatment. Representative video. TC-core (green), AP1 (red).

Supplemental Video 6. Co-trafficking of TC-core HCV with AP1 upon sunitinib treatment. Representative video. TC-core (green), AP1 (red).






Supplemental Video 7. Co-trafficking of TC-core HCV with AP1 upon sunitinib treatment. Representative video. TC-core (green), AP1 (red).

Supplemental Video 8. Co-trafficking of TC-core HCV with AP2 upon vehicle treatment. Representative video. TC-core (green), AP2 (red).



Supplemental Video 9. Co-trafficking of TC-core HCV with AP2 upon sunitinib treatment. Representative video. TC-core (green), AP2 (red).

Supplemental Video 10. Co-trafficking of TC-core HCV with AP2 upon erlotinib treatment. Representative video. TC-core (green), AP2 (red).






Full uncut gel for Figure 1A







Full uncut gel for Figure 1E




Full uncut gel for Figure 2A




Full uncut gel for Figure 2E






E
siRNA: NT AAK1






siRNA: NT GAK



Full uncut gel for Figure 6D



Full uncut gel for Figure 6E



Full uncut gel for Figure 6G

